Log in or Sign up for Free to view tailored content for your specialty!
Oncology News
National Liver Conference to cover ‘tsunami’ of new data on liver disease
SAN ANTONIO — The National Liver Congress will convene October 25th, providing a broad scientific program and exhibit of products and services important for all practitioners involved in the care of patients with liver disease.
VIDEO: Pediatric hepatoblastoma ‘tip of the iceberg’ in predicting future disease
CHICAGO — In this exclusive video from NASPGHAN 2019, Hassan M. Abdullah, MD, from the Rainbow Babies and Children’s Hospital in Cleveland, Ohio, discusses details from his poster presentation on the correlation between adenomatous polyposis coli gene mutations with pediatric hepatoblastoma.
Log in or Sign up for Free to view tailored content for your specialty!
Atezolizumab-bevacizumab combination extends survival in unresectable HCC
The combination of atezolizumab and bevacizumab prolonged survival compared with standard-of-care sorafenib for patients with unresectable hepatocellular carcinoma who had not received prior systemic therapy, according to topline data from the phase 3 IMbrave150 study.
HCV cure improves survival in post-DAA liver cancer development
Patients who developed hepatitis C-related hepatocellular carcinoma after achieving sustained virologic response with interferon-free direct-acting antivirals had a 60% to 70% improvement in 5-year survival compared with untreated patients.
NASPGHAN 2019 chronic liver disease symposium provides update for GIs
CHICAGO — During this year’s North American Society for Pediatric Gastroenterology, Hepatology & Nutrition annual meeting, Mercedes Martinez, MD, from the New York-Presbyterian Columbia University Irving Medical Center in New York, will co-host the Single Topic Symposium on Chronic Liver Disease Management for the Gastroenterologist.
HIV/HCV vs. HCV monoinfection present similar liver cancer rates
In contrast to previous study results, hepatocellular carcinoma and decompensated cirrhosis rates were similar between patients coinfected with hepatitis C and HIV and those with hepatitis C alone, according to data.
Liver cancer pipeline: 6 latest reports
As liver cancer rates continue to increase globally, researchers have focused on novel treatment options including combination therapies and second-line options for patients with insufficient response to initial therapy.
Fotivda, Imfinzi combination trial for liver cancer begins enrollment
AVEO Oncology initiated enrollment in an early trial of a combination therapy using Fotivda and Imfinzi for the treatment of hepatocellular carcinoma with no prior systemic therapy, according to a press release.
FGFR inhibitor improves survival in previously treated cholangiocarcinoma
Incyte announced positive overall response rate and progression-free survival results for pemigatinib, a selective fibroblast growth factor receptor inhibitor under evaluation for patients who failed previous treatment for advanced or metastatic cholangiocarcinoma, according to a press release.
Statins reduce liver cancer risk in patients with chronic HBV
Statin therapy correlated with a reduced risk for hepatocellular carcinoma in patients with chronic hepatitis B, according to results published in Hepatology.
-
Headline News
FDA warns of potential liver injury with Veozah for menopausal hot flashes
September 12, 20242 min read -
Headline News
Video games improved mental health during COVID-19 pandemic
September 12, 20242 min read -
Headline NewsSeptember 12, 20240 min read
-
Headline News
FDA warns of potential liver injury with Veozah for menopausal hot flashes
September 12, 20242 min read -
Headline News
Video games improved mental health during COVID-19 pandemic
September 12, 20242 min read -
Headline NewsSeptember 12, 20240 min read